Fundraising Fox
KiraGen Bio
Founded 2023 · 6 employees on LinkedIn · 5 known investors
Find your way into KiraGen Bio
Sign up to see every warm intro you have to KiraGen Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the KiraGen Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
KiraGen Bio develops cell-therapy approaches aimed at treating brain cancers, with a focus on therapies designed to remain functional under suppressive tumor conditions. Its work targets pediatric brain cancers such as diffuse midline glioma (DMG) and DIPG.
Founders & leadership
KiraGen Bio was founded in 2023 by Aaron Edwards and Ryan Murray, PhD.
AE
Aaron EdwardsCo-Founder/CEOAaron Edwards holds an MS/MBA in Biotechnology from Harvard Business School and previously held leadership positions at Beam Therapeutics and bluebird bio, with over a decade of experience in gene editing, cell therapy, immunotherapy, and mRNA therapeutics. He founded KiraGen Bio to develop gene-edited, donor-derived cell therapies designed to overcome suppression in the tumor microenvironment.
RM
Ryan Murray, PhDCo-Founder & Chief Scientific OfficerRyan Murray holds a PhD and founded KiraGen Bio, which develops gene-edited cell therapies designed to resist tumor microenvironment suppression through multiple targeted genetic modifications.
Investors · 5
2048 Ventureslisted by 2048 VenturesNew York · $500K – $3M
How we know: 2048 Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
__Twitter.png)
In the news
Frequently asked questions
- What does KiraGen Bio do?
- KiraGen Bio develops cell-therapy approaches aimed at treating brain cancers, with a focus on therapies designed to remain functional under suppressive tumor conditions. Its work targets pediatric brain cancers such as diffuse midline glioma (DMG) and DIPG.
- Who founded KiraGen Bio?
- KiraGen Bio was founded by Aaron Edwards, Ryan Murray, PhD in 2023.
- Who are KiraGen Bio's investors?
- KiraGen Bio's investors include 2048 Ventures, Fifty Years, Gaingels, ZAKA VC, Conscience VC.